Leap Therapeutics

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Our mission is to develop and commercialize targeted and immuno-oncology therapies to improve the lives of cancer patients.

Our vision is to become a trusted and respected leader in the targeted and immuno-oncology markets with a unique portfolio of innovative treatments and a competitive consumer-oriented commercial strategy.

Leap Therapeutics has been recognized for its pioneering work in the oncology space, including being honored with the 2017 Rare Disease Award for Overall Excellence by the Global Genes Project, being named among the 2017 Fierce 15 companies selected by FierceBiotech, and being recognized as a finalist in the 10th Annual Biotech Showcase Awards Program in 2018.